Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 14,401–14,500 of 15,747
Skrzat‐Klapaczyńska, A., Kowalska, J. D., Fijołek, F., Paciorek, M., Bieńkowski, C., Krogulec, D., & Horban, A. (2024) · Journal of Virus Eradication · doi:10.1016/j.jve.2024.100377 · Cited by 1
THE EFFECT OF VACCINATON ON COVID-19 DEATHS: A RESEARCH ACCORDING TO COUNTRIES' INCOME GROUPS
ŞENOL, O., ÇIRAKLI, Ü., & GÖKKAYA, D. (2023) · Mehmet Akif Ersoy Üniversitesi İktisadi ve İdari Bilimler Fakültesi Dergisi · doi:10.30798/makuiibf.1033552
Russo, C., Fusco, C., Carbone, F., Micillo, T., Rocca, C. L., Rosa, G. D., Marino, V. D., Ruggiero, K., Garziano, F., Perna, F., et al. (2026) · Clinical Immunology · doi:10.1016/j.clim.2026.110683
Knowledge, Attitude, and Perception of Youth Population in Indonesia toward COVID-19 Vaccination
Alfian Nurfaizi, '., Lelyana Sih Afgriyuspita, '., Ni Made Adnya Suasti, '., et al. (2023) · Asian Journal of Health Research · doi:10.55561/ajhr.v2i1
Manickum, V. K., & Mathibe, L. J. (2025) · Vaccines · doi:10.3390/vaccines13111143
“Pfizer, with a 95% efficacy and strong safety profile [17], was the preferred vaccine in KZN, recording PUBS and PRIVS VURs of 78.7% and 104.4%, respectively.”
InfluentialAfzal, S. M., Mohamed, Z. A., Sengupta, M., Panjaliya, R. K., Das, P. K., Munshi, A., Li, J., Wen, J., Li, F., & Banerjee, S. (2025) · Current Clinical Microbiology Reports · doi:10.1007/s40588-025-00262-z · Cited by 1
Moon, S. M., An, J. N., Kwon, J. H., Kim, S. G., & Kim, H. W. (2025) · Microorganisms · doi:10.3390/microorganisms13102362
“Heterologous prime-boost vaccination strategies have emerged as a critical approach for COVID-19 immunization, particularly driven by vaccine supply constraints and the need to optimize immune responses against emerging variants [19,20].”
Wang, D., Wang, H., Wan, W., Zhu, Z., Sho, T., Zheng, Y., Zhang, X., Dou, L., Ding, Q., Yu, L., et al. (2025) · eLife · doi:10.7554/elife.97621.2
Appeltshauser, L., Ruprecht, C., Reusch, J., et al. (2026) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70117
“COVID-19 vaccination can reduce the risk of SARS- CoV-2 infection, severe COVID-19 disease course, and post-acute COVID-19 sequelae, which might indirectly lower the risk for autoimmune complications [46–48].”
COVID-19 vaccines-related adverse events and associated factors reported among adult Egyptians
Ghazawy, E. R., Ewis, A. A., Khalil, D. M., Alkilany, S. F., Nafady, S., Ewis, H., Mohammed, M. Z., & Abdelrehim, M. (2023) · Journal of Public Health and Development · doi:10.55131/jphd/2023/210104 · Cited by 1
SARS-COV-2. Origen, vacunas, variantes y el futuro de la pandemia
Delfraro, A. (2021) · Revista Educación en Ciencias Biológicas · doi:10.36861/recb.6.1.4
HEALTHCARE WORKERS’ ATTITUDE TOWARD COVID-19 VACCINE IN DUHOK GOVERNORATE
DAWOD, S. B., & Ismail, K. H. (2023) · Duhok Medical Journal · doi:10.31386/dmj.2023.17.1.10
Sarfraz, U. S. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-1982-7.ch001
Kidney Disease and Diabetic Patients
Ministry of Health, S. A., Binjumaiah, S. Q. A., Abodabeel, A. H., Ministry of Health, S. A., Alotaibi, K. N., Ministry of Health, S. A., Alotaibi, B. M. G., Ministry of Health, S. A., Alenezi, K. R. A., Ministry of Health, S. A., et al. (2023) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v3-i11-74 · Cited by 1
Causally Sound Priors for Binary Experiments
Irons, N. J., & Cinelli, C. L. K. (2025) · Bayesian Analysis · doi:10.1214/25-ba1506 · Cited by 1
Molecular signature of COVID-19 prior to its exacerbation by multi-omics survey
Suzuki, T., Kita, Y., Yanagida, K., Maeda, K., Hashidate‐Yoshida, T., Nakanishi, H., Ohto‐Nakanishi, T., Terada-Hirashima, J., Tsujimoto, Y., Hojo, M., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0352423
Posicionamento da ASBAI sobre dose adicional e intercambialidade de vacinas contra a COVID-19
Junior, P. F. G.-B., Diniz, L. D. C., Goudouris, E., Marinho, A. K. B. B., Vasconcelos, D. D. M., Rubini, N. D. P. M., & SARINHO, E. S. C. (2021) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20210035
Analysis and Comparison of the Safety among COVID-19 Vaccines: A Systematic Review
Mostafa, A., & Ehab, H. (2026) · International Journal of Clinical Medical Research · doi:10.61466/ijcmr4020001
“However, like all vaccines, they can cause side effects, which are generally mild and short-term 14, 15 .”
InfluentialAlrasheedi, A. (2024) · Journal of Medical and Health Studies · doi:10.32996/jmhs.2024.5.1.11 · Cited by 1
“…contain this emerging virus, scientists rapidly developed a COVID-19 vaccine through global collaboration between governments, pharmaceutical companies, and academic institutions, leading to the administration of the first COVID-19 outside of clinical trials in December 2020 (Polack et al., 2020).”
BackgroundD’Amico, C., Miska, M., Saarinen, S., Säkkinen, V., & Kostiainen, M. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.25.734245 · Cited by 1
DeDiego, M. L., Portilla, Y., López-García, D., Daviu, N., Vázquez-Utrilla, P., Gallo‐Córdova, Á., Morales, M. P., & Barber, D. F. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837672967-00330 · Cited by 1
Sun, Y., Liu, W., Zhang, G., & Shi, P. (2024) · GeoHealth · doi:10.1029/2024gh001025 · Cited by 2
COVID-19 and Solid Organ Transplantation: What We Learned and Where We are Going
Huang, J., & Pouch, S. M. (2026) · Current Infectious Disease Reports · doi:10.1007/s11908-026-00881-7
Does COVID-19 Vaccination Protect Contact Persons? A Systematic Review
Kampf, G. (2024) · Hygiene · doi:10.3390/hygiene4010003 · Cited by 1
Salvati, L., Carria, M. D., Parronchi, P., et al. (2026) · ASIDE Case Reports · doi:10.71079/aside.cr.021426352
“They have demonstrated an acceptable safety profile across diverse populations, including individuals with autoimmune rheumatic diseases [2–5].”
Sandoval, M. A., Li, Q., Shi, R., Giri, B. R., Yanwinitchai, S., Southard, B., Ni, H., Owens, D. E., Williams, R. O., Weissman, D., et al. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127318
Rocha, A., Milan, E. P., Caminha, R. O. D. C., et al. (2024) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v27i1.613_eng
Qahtani, A. A. A., Korairi, H., Alzaedy, M. A., Nasher, M. A. A., Alshahrani, A. S., Mohamed, N. S., Alzahrani, O. M., Ahamed, K. M. A., Ali, J. H. A., Alqahtani, M. A., et al. (2025) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2025.101975
Intawong, K., Chariyalertsak, S., Chalom, K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2427841/v1
Balar, P. C., Bedse, A. P., Chavda, V. P., Umeyor, C. E., Kolekar, P., Ogbonna, B. O., Anure, A., Eze, D. U., Dodiya, P., & Patravale, V. B. (2025) · Wiley eBooks · doi:10.1002/9781394237654.ch4
Campbell, M., & Jacques, R. (2023) · Wiley eBooks · doi:10.1002/9781119401407.ch1
Bonetti, G., Chitoni, G., Bettinardi, A., et al. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07458-9
Finberg, R. W. (2021) · The Conversation · doi:10.64628/aai.gx96xwguf
Hellgren, F., Cerveira, R. A., Lindgren, G., Chen, P., Lenart, K., Ols, S., Cagigi, A., Valentini, D., Barranco, M. R., Vitus, E. S., et al. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70077
Sahu, I., Engelmann, F., Weidensee, B., Ganesan, H., Brucker, S. Y., Singh, Y., & Salker, M. S. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07346-5
“Several caveats of IVT-mRNA need to be addressed including; potential immunogenicity mediated by the immune system (pattern recognition receptors) and nucleases degrading single-stranded mRNA [20, 25].”
Soni, V., Joshi, S., Deep, K., & Pant, M. (2024) · Lecture notes in networks and systems · doi:10.1007/978-981-97-3292-0_62
Choi, H., Halanych, C., Kasberg, W., Testa, M. D., Rubin-Elgressy, S., Nguyen, P., Walpita, D., Tsang, A., Cortes, D., Song, E. Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.02.697412 · Cited by 1
Causes and Consequences of Coronavirus Spike Protein Variability
Zech, F., Jung, C., Jacob, T., & Kirchhoff, F. (2024) · Viruses · doi:10.3390/v16020177 · Cited by 1
“Although alternative receptors for SARS-CoV-2 entry have been reported, development of resistance to ACE2 mimics by a switch in receptor The initial vaccines developed against SARS-CoV-2 were designed based on the Hu-1 variant, the earliest strain of the virus [133–135].”
MethodPerrone, C., Schilling, W. H., Callery, J. J., Ashley, E. A., Chambers, M., Chase, H., Dahal, P., Kanthawang, N., Nedsuwan, S., Hanboonkunupakarn, B., et al. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16880.3 · Cited by 2
How ophthalmology practice changed over 2 years of coronavirus disease 2019 pandemic
Eissa, M. A., Abdullatif, A. M., Attya, M., et al. (2022) · Journal of the Egyptian Ophthalmological Society · doi:10.4103/ejos.ejos_38_22
Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI
Tian, J., Tran, K. T. M., Pogostin, B. H., Sheridan, O., Mursalova, S., Lee, A. H., Liu, S., Hamkins, J., Antov, D., Power, A. L., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03331-w · Cited by 2
What we learned about headache during the COVID-19 pandemic: literature review
Januškevičiūtė, E., Grigaitė, J., & Ryliškienė, K. (2023) · Neurologijos seminarai · doi:10.29014/ns.2022.26.16
Adler, A. C., & Lin, E. E. (2021) · British Journal of Anaesthesia · doi:10.1016/j.bja.2021.01.025
Wang, S., Zhong, Y., Wang, C., Tian, M., Bennett, J. L., Bliss‐Moreau, E., Xue, Y., Yu, C., Hou, X., Zheng, Y. Y., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2538147123 · Cited by 2
Shen, Y., Wei, Y., Weng, W., Yang, C., Wu, C., Liu, X., Xu, X., Qi, J., Zhang, W., & Ding, N. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.176034
Pizzichetti, C., Latino, I., Virgilio, T., Capucetti, A., Chahine, K., Cascione, L., Moro, S. G., Brügger, M., Kozarac, N., Pulfer, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.659539
“The emergence of symptomatic coronavirus disease 2019 (COVID-19) across the planet triggered a global race for the development of an effective vaccine.”
2) Status of Vaccine Development for COVID-19
Watanabe, T. (2021) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.110.2099
Mweetwa, L. L., Tlhoiwe, D., Tlhoiwe, T., Tshiamo, K. O., Munsaka, S. M., Kenaope, T. J., Mothibe, G., Mokate, O., & Oluwabusola, E. T. (2022) · Medical Research Archives · doi:10.18103/mra.v10i9.3027 · Cited by 1
Mirattanaphrai, S., Suphannaphong, M., & Sriratanaban, J. (2024) · Outbreak Surveillance Investigation & Response (OSIR) Journal · doi:10.59096/osir.v17i4.268653
“20 As demonstrated in study, stratifying AEFI occurrences of various vaccination strategies and sequences by age can help revealing significant insights into demographic influences on vaccine safety.”
Assessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-AnalysisPreprint
Hoang, T. N. A., Quach, H., Hoang, N. V., Tran, T. V., Thái, P. Q., & VOGT, F. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161714
Munawwarah, W., Kurniawati, N., & Agustina, D. (2022) · Indonesian Journal of Physiotherapy · doi:10.52019/ijpt.v1i2.3322
The Impact of Coronavirus Disease 2019 Vaccines on the Immune System: A Narrative Review
Urazayeva, S. T., & Tussupkaliyeva, K. (2025) · West Kazakhstan Public Health Journal · doi:10.4103/wkpj.wkpj_3_26
Changes Over Time in COVID-19 Vaccination Inequalities in Eight Large U.S. CitiesPreprint
Gaddis, S. M., Carey, C. M., & DiRago, N. V. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.3975859
Main-chain disulfide-linked cationic polycarbonates for local mRNA delivery
Gong, X., Yang, Y. L., Wang, Z., Zhang, Q., & Liu, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126179
Dose-dependent interferon programs in myeloid cells after mRNA and adenovirus COVID-19 vaccinationPreprint
Eryilmaz, G. N., Yazici, Y. Y., Marcheş, R., Mimitou, E. P., Kenyon‐Pesce, L., Handrjek, K., Jangra, S., Schotsaert, M., García‐Sastre, A., Kuchel, G. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.15.668720
Banerjee, A., Garg, R., Liu, Q., van Kessel, J., Asavajaru, A., Uhlemann, E.-M. E., Joessel, M., Hamonic, G., Khatooni, Z., Kroeker, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3656968/v1
COVID-19 Vaccine–Associated Myocarditis Considerations for Competitive Athletes
Tso, J., & Kim, J. H. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-01009-z
Biocompatible nanosystems for innovative applications of small therapeutic molecules
Andreana, I. (2022) · theses.fr (ABES) · doi:10.70675/dde2af37z7946z4047zb96bz1053d340e54f
Nealon, J., Mefsin, Y. M., McMenamin, M. E., Ainslie, K. E. C., & Cowling, B. J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4130010
Zhang, Z., Zang, Y., Yang, J., Yang, K., Zhao, Y., Zhang, W., Guo, S., Han, C., Liu, C., Mi, X., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3908849/v1
Tunà, Z., Güngör, S., Aslı, C. A. N., & FARZİNMOGHADDAM, F. (2023) · Gazi Sağlık Bilimleri Dergisi · doi:10.52881/gsbdergi.1286924
Lu, X., Hayashi, H., Ishikawa, E., Takeuchi, Y., Dychiao, J. V. T., Hironori Nakagami, A., & Yamasaki, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.06.543529
Signal detection of COVID ‐19 vaccines adverse events using spontaneous reports from South Korea
Jeong, H. S., & Chun, B. C. (2023) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5629 · Cited by 1
“In clinical trials of Pfizer vaccine, frequently reported local reactions were injection site pain, and systemic reactions were fatigue, headache, and myalgia.(27) In clinical trials of the Moderna vaccine, frequently reported local reactions were injection site pain, and systemic reactions were fatigue, headache, and…”
BackgroundPost-booster longitudinal plasma proteomic changes following BNT162b2 COVID-19 vaccination in Qatar
Bentebbal, S., Zaqout, A., Meqbel, B., Bensmail, I., Aldushain, A., de la Fuente, A., Thomas, R., Naik, A., Shaath, H., Al-Akl, N. S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1762522
Keinan‐Boker, L., Fluss, R., Dichtiar, R., Rosenberg, A., Lassan, M. B., & Huppert, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3465256/v1
Mondi, A., Mastrorosa, I., Navarra, A., Cimaglia, C., Pinnetti, C., Mazzotta, V., Agresta, A., Corpolongo, A., Zolezzi, A., Moghazi, S. A., et al. (2024) · Vaccines · doi:10.3390/vaccines12091018 · Cited by 1
“COVID-19 vaccines demonstrated a high effectiveness in reducing the risk of SARS-CoV-2 infections and the burden of COVID-19 severe disease and mortality in both clinical trials [5,6] and in the real-world setting [7,8].”
BackgroundEpidemiology, evolution, and phylogeny of coronaviruses
Basharat, B., Jahan, N., Badar, M. S., Saman, N., Faizi, Q. A., & Asaf, B. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95374-0.00012-9
Lee, D. B., Kim, H., Jeong, J. H., Jang, U. S., Chang, Y. Y., Roh, S., Jeon, H., Kim, E. J., Han, S. Y., Maeng, J. Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.18.480994
COVID-19 Diagnostic Tests, Vaccines and Medicines in Its Treatment; Current status
Salmanoglu, D. S., Çalışkan, E. E., Meliz, S. O. F. U., Yiğit, U., & Uyanıkgil, E. Ö. Ç. (2021) · Uludağ Üniversitesi Tıp Fakültesi Dergisi
Investigating Dermatological Side Effects of COVID‐19 Vaccination Among the Bangladeshi Population
Tabassum, S., Roni, M. R. H., Rahat, M. T. I., Sumi, M. S. A., Resma, M. N. J., Bhuiyan, M. A. R., & Kibria, M. K. (2026) · Dermatologic Therapy · doi:10.1155/dth/9521685
Nishihara, T., Shibata, M., Ohashi, A., Hiyama, K., Yamashita, T., Kuroiwa, M., & Sudo, N. (2023) · BioPsychoSocial Medicine · doi:10.1186/s13030-023-00296-z
Silva, R., Silva, F., Mendonça, L., Pereira, L., Oliveira, A., Ramos, A., Cardoso, M., Malheiro, A., & Guimarães, J. T. (2022) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2022.03.171
“Port J Nephrol Hypert 2022; 36(1): 50-52 51 SARS-CoV-2 antibody responses in infection-naive or previously infected peritoneal dialysis patients after 2 doses of the BNT162b2 vaccine”
BackgroundMethodInfluentialPetrie, J. G., King, J. P., McClure, D. L., Rolfes, M. A. R., Meece, J. K., Belongia, E. A., & McLean, H. Q. (2022) · medRxiv · doi:10.1101/2022.04.15.22273915
“3 Clinical trials supporting emergency use authorization of COVID-19 messenger RNA (mRNA) vaccines in the United States (US) estimated the efficacy of a 2-dose series to be >90% in preventing symptomatic infection[1,2].”
BackgroundNogami, M., Hoshi, T., Toukairin, Y., Arai, T., & Nishio, T. (2023) · Research Square · doi:10.21203/rs.3.rs-3622874/v1
Biomedical advances in the treatment of COVID-19
Iyer, R. K., Venkataramanan, V., Pierce, G. N., Thakkar, N., Natarajan, V., & Chockalingam, A. (2021) · International Journal of Noncommunicable Diseases · doi:10.4103/2468-8827.330647
Petersheim, D., & Klein, C. (2025) · Frontiers in Science · doi:10.3389/fsci.2025.1631904
American Covid: An Econometric Analysis of VariantsPreprint
McIntosh, J. (2022) · medRxiv · doi:10.1101/2022.06.09.22276226
Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
Kiewisz, J., Drzyzga, D., Rozanska, K., Krzynowek, E., & Łukaszuk, K. (2022) · Vaccines · doi:10.3390/vaccines10050640
“Adverse reactions like lymphadenopathy, arrhythmia, hemorrhagic stroke, myocardial infarction were also monitored [1].”
BackgroundMyths and Facts Associated with Vaccine Development: Challenges, Safety, and Efficacy
Vihal, S., Kaur, S. D., Vivek, P., Kumari, N., Kumbham, S., & Salihu, M. B. (2026) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-032-29006-9_15
Chikamatsu, G., Izumo, T., Shiozaki, E., Ogawa, Y., Yoshimura, S., Matsuo, A., Okamura, K., Takahira, R., Sadakata, E., Morofuji, Y., et al. (2025) · Medical Reports · doi:10.1016/j.hmedic.2025.100367
CircRNA Based Bi-Antigen Vaccines Against Mpox Virus Induces Potent and Durable Protection in MicePreprint
Zhou, J., Wang, C., Wu, Y., Zhao, B., Yang, Y., Ye, T., Zhang, K., Li, F., Hu, J., Zhang, K., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5370492
Overview on Vaccine Efficacy, An
Bose, M., & Biswas, A. (2025) · International Encyclopedia of Statistical Science · doi:10.1007/978-3-662-69359-9_21
Jin, Z., Wu, J., Huang, T., Zhao, K., Zhang, M., Liu, J., Song, J., Yin, H. H., Wu, X., Liu, J., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12053-4
“Despite the rapid development and assessment of the vaccine, phase III clinical trials demonstrated nearly 90% efficacy [6, 7].”
Eyelid erythema after coronavirus vaccination
Bárcena-Dahl, A., Bonivento-Martínez, V., & de Pipaón, M. R.-P. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.06.021
Solomon, O., Adams, C., Horton, M. K., Wong, M. P., Meas, M., Shao, X., Fedrigo, I., Hernandez, S., Quach, H., Quach, D. L., et al. (2022) · medRxiv · doi:10.1101/2022.09.30.22280166
Madadha, M. E. A., Rayyan, R., Ahmed, K., Al-Sanouri, N., Demour, S. A., & Ahmad, M. M. (2022) · Cogent Public Health · doi:10.1080/27707571.2022.2145756
Selection of Short 5′-UTR of Chemically Synthesized mRNA to Improve Translation Efficiency
Ohashi, S., Ishiguro, S., Fukunaga, T., Matsumoto, A., Hirata, M., Inagaki, M., Abe, N., Hashiya, F., & Abe, H. (2025) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c25-00048
Vogel, A. B., Lui, B. G., Tompkins, K. R., Kanevsky, I., Muik, A., Krumm, S. A., Güler, A., Maddur, M. S., Walzer, K. C., Witzel, S., et al. (2026) · npj Vaccines · doi:10.1038/s41541-025-01365-w
Self-citationExamination of Attitudes of Healthcare Professionals in Turkey towards Covid-19 Vaccines
Bostan, S., İZGÜDEN, D., Akbolat, M., & Erdem, R. (2023) · ADAM AKADEMİ Sosyal Bilimler Dergisi · doi:10.31679/adamakademi.1136631
Development of donor specific antibodies after SARS-CoV-2 vaccination: What do we know so far?
Daoud, A., Soliman, K. M. M., Salas, M. A. P., et al. (2024) · World Journal of Meta-Analysis · doi:10.13105/wjma.v12.i2.91264
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.